GEVA
Synageva BioPharma Corp.
NasdaqGS
People also watch:CLVSRCPTANACAEGRKYTH
238.600.00 (0.00%)
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Prev Close238.60
Open0.00
Bid0.00 x
Ask0.00 x
52wk Range
Day's Range0.00 - 0.00
Volume0
Avg Vol (3m)N/A
As of 3:59 PM EDT. Market closed.
  • Reuters11 months ago

    Alexion gets EU approval for drug acquired in Synageva deal

    Ten weeks after closing its $8.4 billion purchase of Synageva BioPharma Corp, Alexion Pharmaceuticals Inc on Tuesday announced European approval for the key drug acquired through the deal, an enzyme-replacement therapy for an ultra-rare, life threatening disease. The treatments are awaiting U.S. approval decisions after receiving breakthrough therapy designations from the Food and Drug Administration. "This is sort of a momentous year for us," Alexion Chief Executive David Hallal said in an interview.

  • GuruFocus.com11 months ago

    Columbia Wanger Sells 22 Stakes in Second Quarter

    Chicago-based Columbia Wanger (Trades, Portfolio) serves mostly investment companies, managing mutual funds for its clients.